CytomX Therapeutics, Inc. $CTMX Shares Purchased by Dimensional Fund Advisors LP

Key Points

• Dimensional Fund Advisors increased its CytomX Therapeutics stake by 49.7% in the first quarter, owning 1.93 million shares valued at approximately $9.1 million. Institutional investors collectively hold 67.77% of CTMX.
• Analyst sentiment is broadly positive, with an average “Buy” rating and a consensus price target of $12.10, despite individual upgrades, downgrades, and a target reduction by HC Wainwright.
• CytomX reported a quarterly loss of $0.09 per share and revenue of $1.42 million, missing analyst expectations for both earnings and revenue. Shares opened at $3.46, while the company continues developing its Probody-based cancer therapies.

Dimensional Fund Advisors LP lifted its holdings in CytomX Therapeutics, Inc. (NASDAQ:CTMX - Free Report) by 49.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,930,920 shares of the biotechnology company's stock after purchasing an additional 641,264 shares during the period. Dimensional Fund Advisors LP owned about 1.13% of CytomX Therapeutics worth $9,071,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of CTMX. Orbimed Advisors LLC purchased a new stake in shares of CytomX Therapeutics in the second quarter valued at approximately $19,208,000. Commodore Capital LP purchased a new position in CytomX Therapeutics during the second quarter valued at $17,462,000. Perceptive Advisors LLC purchased a new position in CytomX Therapeutics during the second quarter valued at $15,876,000. State Street Corp grew its position in shares of CytomX Therapeutics by 697.1% in the fourth quarter. State Street Corp now owns 5,140,931 shares of the biotechnology company's stock valued at $21,900,000 after purchasing an additional 4,495,949 shares during the period. Finally, ADAR1 Capital Management LLC grew its position in shares of CytomX Therapeutics by 31.3% in the third quarter. ADAR1 Capital Management LLC now owns 4,045,414 shares of the biotechnology company's stock valued at $12,905,000 after purchasing an additional 964,000 shares during the period. Institutional investors and hedge funds own 67.77% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on CTMX. Zacks Research raised shares of CytomX Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, July 21st. Wall Street Zen upgraded CytomX Therapeutics from a "strong sell" rating to a "sell" rating in a research note on Saturday, May 9th. Wolfe Research started coverage on CytomX Therapeutics in a report on Tuesday, May 19th. They set an "outperform" rating and a $6.00 target price for the company. HC Wainwright decreased their target price on CytomX Therapeutics from $17.00 to $11.00 and set a "buy" rating on the stock in a research report on Monday, May 11th. Finally, Weiss Ratings restated a "sell (d)" rating on shares of CytomX Therapeutics in a research report on Tuesday, June 16th. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, CytomX Therapeutics currently has an average rating of "Buy" and a consensus price target of $12.10.

CytomX Therapeutics Stock Performance

NASDAQ:CTMX opened at $3.46 on Monday. CytomX Therapeutics, Inc. has a one year low of $1.72 and a one year high of $8.21. The stock has a market cap of $588.86 million, a PE ratio of -6.92 and a beta of 2.12. The stock has a 50 day moving average price of $3.35 and a 200 day moving average price of $4.26.

CytomX Therapeutics (NASDAQ:CTMX - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The biotechnology company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.01). CytomX Therapeutics had a negative net margin of 435.21% and a negative return on equity of 38.46%. The firm had revenue of $1.42 million for the quarter, compared to analyst estimates of $12.39 million. As a group, analysts predict that CytomX Therapeutics, Inc. will post -0.45 earnings per share for the current fiscal year.

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX's pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.

Want to see what other hedge funds are holding CTMX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CytomX Therapeutics, Inc. (NASDAQ:CTMX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source